Biotech News

Zentalis Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Updates

Zentalis (ZNTL)ZentalisEarnings

Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of an investigational, potentially first-in-class WEE1 inhibitor, azenosertib, as a biomarker-driven treatment approach for ovarian cancer, today announced financial results for the third quarter ended September 30, 2026, and highlighted recent business updates.

Related news

Zentalis

Cell-Cycle Oncology Company Zentalis Pharmaceuticals develops azenosertib, an oral inhibitor of WEE1, a regulator of DNA-damage checkpoints and cell-cycle progression. Cyclin E1-Positive Ovarian Cancer The lead program targets platinum-resistant ovarian cancers with Cyclin E1 expression, where replication stress may create heightened...

Recent company news

Stock data

Close
1.36 USD
Market cap
281.19M USD
Exchange
NASDAQ
Sector
Small Molecule Drugs
Location
United States